Coherus’ presentation was titled as, “Characterization of CHS-1000, an Fc-modified anti-ILT4 monoclonal antibody for reprogramming suppressive myeloid cells in solid tumors”
The preclinical study demonstrated CHS-1000’s (mAb) ability of blocking ILT4’s interaction with HLA-A & HLA-G that reversed ILT4-mediated immunosuppression and activated M1 macrophages, dendritic cells & T cells to elevate pro-inflammatory cytokine release in in vitro assays. It specifically & selectively interacts with ILT4 (LILRB2) without reacting with other members of the LILRB family
The company anticipates the IND submission in Q2’24 to initiate its clinical evaluation later in 2024
Ref: Coherus | Image: Coherus
Related Post:- Coherus BioSciences Launches an On Body Injector for the Administration of Udenyca (biosimiolar, pegfilgrastim) to Treat Non-Myeloid Malignancies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
